<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839059</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG08-07</org_study_id>
    <nct_id>NCT00839059</nct_id>
  </id_info>
  <brief_title>Lenalidomide In Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Open-Label, Multi-Center Phase I Dose-Escalation Study With Lenalidomide In Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, multi-center, dose-escalation study of lenalidomide in adult&#xD;
      patients with newly diagnosed, relapsed or refractory acute myeloid leukemia. All patients&#xD;
      will receive lenalidomide per oral daily (starting dose is 25 mg/d). Cohorts of 3 patients&#xD;
      (to be expanded up to 6 if 1 dose-limiting toxicity (DLT) is observed among the first 3&#xD;
      patients) will be sequentially allotted to progressively higher dose levels of lenalidomide&#xD;
      on the basis of the presence and severity of lenalidomide-related toxicity or lenalidomide&#xD;
      related serious adverse reactions encountered in the first cycle. For the purpose of this&#xD;
      study, patients' enrollment will continue until the maximum tolerated dose (MTD) will be&#xD;
      determined and characterized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six&#xD;
    participating centres&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities (DLTs), Maximum tolerated dose (MTD)</measure>
    <time_frame>1-56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the pharmacokinetic profile of lenalidomide</measure>
    <time_frame>1st and 8th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response, as defined using the revised recommendations of the International Working Group for diagnosis, standardization of response criteria in Acute Myeloid Leukemia for AML</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Dose escalation:&#xD;
Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.&#xD;
Duration of the first cycle: 56days, each following cycle will last 28 days</description>
    <arm_group_label>Lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease state:&#xD;
&#xD;
          -  Age &gt; 70 years newly diagnosed AML (including de novo, s-AML, t-AML)considered&#xD;
             ineligible for intensive treatment. Ineligibility for intensive treatment has to be&#xD;
             documented within the case report forms (Medical/Oncologic History).&#xD;
&#xD;
          -  Age &gt; 60 years relapsed/refractory AML in medically fit patients and newly diagnosed&#xD;
             AML (including de novo, s- AML,t-AML) in medically unfit patients&#xD;
&#xD;
          -  Age 18-60 years: second or higher relapse of AML, not eligible for intensive therapy&#xD;
&#xD;
          -  WBC &lt;20x109/l, pretreatment with hydroxyurea is allowed to lower WBC&#xD;
&#xD;
          -  Prior chemo-immunotherapy and other study-medications must have been completed 2 weeks&#xD;
             before study treatment start. Treatment with hydroxyureas should be discontinued 1 day&#xD;
             before initiating dosing with lenalidomide&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits,treatment plan, laboratory&#xD;
             tests and other study procedures&#xD;
&#xD;
          -  Females of childbearing potential (FCBP)† must agree to use two reliable forms of&#xD;
             contraception simultaneously or to practice complete abstinence from - FCBP must have&#xD;
             two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting&#xD;
             study drug.&#xD;
&#xD;
          -  Male subjects must agree to use a latex condom during sexual contact with females of&#xD;
             childbearing potential while participating in the study and for at least 28 days&#xD;
             following discontinuation from the study even if he has undergone a successful&#xD;
             vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia [t(15;17)]&#xD;
&#xD;
          -  bleeding disorder independent of the AML&#xD;
&#xD;
          -  uncontrolled infection&#xD;
&#xD;
          -  insufficiency of the kidneys (creatinin &gt;1.5x upper normal serum level), of the liver&#xD;
             (bilirubin, AST or AP &gt; 2x upper normal serum level)&#xD;
&#xD;
          -  severe obstructive or restrictive ventilation disorder&#xD;
&#xD;
          -  heart failure NYHA III/IV&#xD;
&#xD;
          -  severe neurological or psychiatric disorder interfering with ability of giving an&#xD;
             informed consent&#xD;
&#xD;
          -  no consent for registration, storage and processing of the individual&#xD;
             disease-characteristics and course&#xD;
&#xD;
          -  peripheral neuropathy&#xD;
&#xD;
          -  Performance status WHO &gt; 2&#xD;
&#xD;
          -  Presence of any medical/psychiatric condition or laboratory abnormalities which may&#xD;
             limit full compliance with the study, increase the risk associated with study&#xD;
             participation or study drug administration, or may interfere with the interpretation&#xD;
             of study results and, in the judgment of the Investigator, would make the patient&#xD;
             inappropriate for entry into this study&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Known positive for HIV or infectious hepatitis, type A, B or C&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide&#xD;
&#xD;
          -  Any prior use of lenalidomide&#xD;
&#xD;
          -  Drug or alcohol abuse within the last 6 months&#xD;
&#xD;
          -  Participating in other studies within the last 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Schlenk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the Johann Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uni-ulm.de/onkologie/AMLSG/index.html</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.kompetenznetz-leukaemie.de</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Reinhard Marre</name_title>
    <organization>University of Ulm</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

